文献速递免疫规划卫生政策与健康促进

芬兰侵袭性肺炎球菌疾病疫苗试验中肺炎球菌结合疫苗的疫苗可预防疾病发病率

Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial.
PubMed 文献 · Vaccine · 2018-01-01

芬兰FinIP试验为群随机双盲试验,儿童按3+1或2+1或补种程序接种PHiD-CV10或乙肝/甲肝疫苗对照。估算疫苗可预防疾病发病率:实验室确诊侵袭性肺炎球菌疾病每10万人年75例,非实验室确诊210例,医院诊断肺炎271例,鼓膜置管1143例,门诊抗菌药物处方11381例。

要点

  • 在接种疫苗的儿童中,超过95%的疾病发作减少见于轻度上呼吸道感染。
  • 严重疾病的疫苗可预防疾病发病率被低估,因多数侵袭性疾病未被常规血培养发现。
  • 使用敏感病例检测评估疫苗可达到的绝对减少对理解疾病负担和成本效果分析至关重要。

核心结论

  • 在歐洲发达 country 环境中,接种疫苗儿童中超过95%的疾病发作减少见于轻度上呼吸道感染。
  • 严重疾病的疫苗可预防疾病发病率被低估,因为多数侵袭性疾病未被常规基于血培养的定义发现。
  • 使用敏感病例检测评估疫苗可达到的绝对减少对于理解完整疾病负担、有效成本效果分析和适当疫苗接种政策决策至关重要。

研究设计与样本

  • 芬兰侵袭性肺炎球菌疾病(FinIP)试验为群随机双盲试验,儿童<19月龄,52个群接种PHiD-CV10,26个群接种乙肝/甲肝疫苗对照,按3+1或2+1程序(婴儿<7月龄)或补种程序(儿童7-18月龄)。
  • 共入组超过47000名儿童;首次接种时<7月龄的接种婴儿30527名。
  • 结局数据通过芬兰常规医疗登记收集,包括THL国家传染病登记、THL护理登记和芬兰社会保险机构福利登记。
  • 盲法随访从首次接种日期(试验入组2009年2月至2010年8月)至2012年1月31日(侵袭性肺炎球菌疾病)或至2011年12月底(其他四项结局)。

主要发现

  • 在首次接种时<7月龄的30527名接种婴儿中,每10万人年的疫苗可预防疾病发病率:实验室确诊侵袭性肺炎球菌疾病为75,非实验室确诊侵袭性肺炎球菌疾病为210,医院诊断肺炎为271,任何鼓膜置管为1143,门诊抗菌药物处方为11381(主要因中耳炎)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 严重疾病的疫苗可预防疾病发病率被低估,因为多数侵袭性疾病未被常规基于血培养的定义发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Estimation of the full disease burden caused by Streptococcus pneumoniae is challenging due to the difficulties in assigning the aetiology especially in lower and upper respiratory infections. We estimated the pneumococcal disease burden by using the vaccine-preventable disease incidence (VPDI) of PHiD-CV10 vaccine (GSK) in our clinical trial setting. Finnish Invasive Pneumococcal disease (FinIP) trial was a cluster-randomized, double-blind trial in children <19 months who received PHiD-CV10 in 52 clusters or hepatitis B/A vaccine as control in 26 clusters according to 3+1 or 2+1 schedules (infants < 7 months) or catch-up schedules (children 7-18 months). Outcome data were collected using Finnish routine health-care registers, consisting of THL National Infectious Diseases Register, THL Care register, and Benefits Register of Social Insurance Institution of Finland. Blinded follow-up lasted from the date of first vaccination (trial enrolment Feb-2009 through Aug-2010) to January 31, 2012 for Invasive Pneumococcal Disease (IPD) and to end of December 2011 for four other outcomes: non-laboratory-confirmed IPD, hospital-diagnosed pneumonia, tympanostomy tube placements, and antimicrobial purchases. VPDI was estimated as difference in disease incidences between PHiD-CV10 clusters and control clusters. Altogether >47,000 children were enrolled. In 30,527 vaccinated infants <7 months at first dose, the VPDIs per 100,000 person-years were 75 for laboratory-confirmed IPD, 210 for non-laboratory-confirmed IPD, 271 for hospital-diagnosed pneumonia, 1143 for any tympanostomy tube placements and 11,381 for antimicrobial outpatient prescription, mainly due to otitis media. In a European developed-country setting, over 95% of the disease episode reductions in vaccinated children were seen in mild upper respiratory infections. The VPDIs of severe diseases are underestimated, because the majority of invasive disease goes undetected with routine blood-culture-based definitions. Evaluation of the absolute reduction achievable with vaccinations using sensitive case detection is essential for understanding the full disease burden, for valid cost-effectiveness analyses and for appropriate vaccination policy decisions. Registration: ClinicalTrials.gov, NCT00861380 and NCT00839254.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Palmu AA, Jokinen J, Nieminen H, et al. Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial. Vaccine. 2018. PMID: 29503110. doi:10.1016/j.vaccine.2018.02.088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。